Envisagenics

Envisagenics is a private, AI-driven biotech founded in 2014, specializing in the discovery of RNA splicing-based drug targets. Its core technology, the SpliceCore® platform, analyzes complex transcriptomic data to identify novel, prevalent, and disease-specific splicing events with high therapeutic potential, primarily in immuno-oncology and neurodegeneration. The company has secured Series B financing and established key research collaborations with major pharmaceutical partners like Bristol Myers Squibb, Biogen, and Johnson & Johnson. Envisagenics operates as a pre-clinical, pre-revenue therapeutics developer, advancing its pipeline through strategic partnerships.

SpliceCore®: A proprietary AI platform that analyzes RNA splicing data to discover novel, prevalent, and disease-specific therapeutic targets. It searches over 14 million splicing events to identify dysregulated splicing with high therapeutic potential and includes SpliceIO™ for identifying splicing-derived neoepitopes for immuno-oncology.

Envisagenics competes with other AI-driven drug discovery companies (e.g., Recursion, Exscientia) and firms specifically targeting RNA splicing (e.g., Stoke Therapeutics, Skyhawk Therapeutics). Its differentiation lies in its specialized focus on splicing-derived targets and its SpliceIO™ module for immuno-oncology neoepitopes.